Safety, tolerability, and anti-fibrotic efficacy of the CBP/-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: an investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study
The fact that the same proteins in these pathways, and even the same mutated residues are involved (Marmion et al., 2023), raises compelling questions, including (i) why the phenotypic presentations are vastly different, and (ii) how we can develop a strategy to identify and predict NDD-related mutations and distinguish them from those related to cancer even though the same residue is mutated
Clinical practice guideline: Irritable bowel syndrome with constipation and functional constipation in the adult
As a persons muscle mass increases, the level of creatine in the blood may also rise
Always swirl gently